Search results
Results from the WOW.Com Content Network
Bayer AG (English: / ˈ b aɪ. ər /, commonly pronounced / ˈ b eɪ ər /; [3] German:) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In 1994, Bayer reacquired full rights to all former Bayer products [8] after they purchased the Winthrop division of over-the-counter drugs from GlaxoSmithKline, and the Miles name was discontinued. In 2012, Bayer relocated the top United States administrative head to the Bayer HealthCare site in Whippany .
Takeda Pharmaceutical: Shire: 62.5 78 Third bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the company, its growth prospects as well as pipeline. [24] 10 2016 Bayer AG: Monsanto Company Inc. 62 81 Bayer initially opened negotiations with an offer of $125 per Monsanto share, however management felt ...
Shares in Bayer dropped as much as 5.7% on Monday after the embattled German company was ordered to pay $2.25 billion in damages, the highest amount yet in its ongoing litigation linked to an ...
In a bid to claw back $2.15 billion, the struggling pharmaceutical giant Bayer CEO is doing away with middle managers and 99% of the company’s 1,362-page corporate handbook, allowing nearly ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
In a bid to claw back $2.15 billion in costs, the chief executive of struggling pharmaceutical giant Bayer announced in early April that the company was eliminating middle managers and allowing ...